Articles in FierceBiotech today. Are other companies/technologies preferred? Is IMGN not a good partner? Or, is IMGN intentionally passing up these type of deals in favor of going alone? Since IMGN has never designed and run a successful phase II, or phase III trial on their own, this could be a risky strategy for investors. Internal development adds time risk since they are slow in development and increases financial risk since running clinical trials is very expensive. I think they have some excellent drug candidates, especially 289, which could be a breakthrough in the right hands. The question remains, is IMGN exec management capable???
Exec management highly questionable. Case in point, IMGN901 combo trial, N901 to be added to SOC because drug has such low toxicity profile. With minimal prior expertise in conducting clinical trials, a special paid for committee of experts was established to help with this effort. Results, after establishing MTD, a vast number of candidates was run thru the trial until it was noted that many of these participants actually couldn't tolerate this MTD and rendered the trial null and void. Many, many months of effort, down the drain.
Adding N901 to SOC clearly placed trial emphasis on making sure that minimal toxicity was introduced by new treatment; don't know what took committee of experts and IMGN clinical trial team so long to identify the screw-up.
Then again, partners aren't really going gangbuster either.
yes, other than Roche/Genentech, the partners are also moving too slow. I agree, IMGN really messed up the 901 trial, the designer should have been fired. I suspect that's why they hired Charlie. It seems they did one trial to define the MTD dose for 901 alone, but nothing for the combo dose.